Navigating Patient Preference and Guidelines as a Fellow  by Gosain, Priyanka
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 4 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 1 2 . 0 0 6FELLOWS-IN-TRAINING & EARLY CAREER PAGENavigating Patient Preference
and Guidelines as a Fellow
Priyanka Gosain, MDA s fellows in training, clinical guidelinesprovide an important foundation for ourlearning. At this stage in our career, we
cannot credibly start an argument with the words
“in my years of practice,” and we often have to settle
for the thrill of “one-upmanship” that comes from
quoting the level of evidence on each guideline
recommendation. As a result, each time a new docu-
ment is published, there is a set of wide-eyed fellows
who open the PDF link, with the excitement of chil-
dren who know they got what they wanted for Christ-
mas. Every time that I apply a Class I guideline
recommendation, I envision myself rounding with
the number of experts in the ﬁeld who contributed
to that document.
Thus, when the new 2013 American College of
Cardiology/American Heart Association guideline on
the treatment of blood cholesterol was released (1), I
downloaded the risk calculator and entered the
outpatient clinic with the conﬁdence that comes with
knowledge. And, when a 45-year-old woman came in
for her ﬁrst visit, I stood prepared, armed with my
calculator. After navigating the complex algorithm,
we reached the part of decision-making that ends
with “patient preference.” Instantly, I went from
rounding with 50 experts in the ﬁeld of lipid disorders
to rounding with each patient, every one of whom is
an expert on his or her own life. Many years from
now, I know I will learn more from each of those pa-
tients than I would learn from the experts. However,
at this stage in my training, in that clinic at that
moment, my recommendation lacked the conviction
that comes from knowing that a formidable panel of
experts would recommend the same treatment plan
for her. After our 30-min discussion, she decided notFrom the Division of Cardiovascular Diseases, Mount Sinai Medical
Center, Miami, Florida.to take a statin. Now, if she has a myocardial infarc-
tion, will I be able to tell myself that she made her
own decision? Did I explain the beneﬁts of statin
therapy? Was my tone appropriate? Did I not dwell
enough on the beneﬁts? Did she really understand
anything that I told her?
The 2013 guideline for management of lipid dis-
orders uses the phrase “patient preference” 17 times
in 4 different contexts (1). The Eighth Joint National
Committee panel hypertension recommendations
also make continual reference to the same phrase
(2), whereas the Seventh Joint National Committee
guideline, published 10 years prior, does not use
the phrase “patient preference” at all (3). The new
guideline on the management of valve diseases uses
the phrase 6 times, upgrading it from a Class IIa to a
Class I recommendation in some instances (4). Most
of these documents start with a preamble that assures
the reader that due consideration was given to pa-
tient preferences. The recent and deliberate addition
of phrases such as “patient preference” to the deci-
sion tree has made some of the recommendations
nonspeciﬁc. The idea behind the gradual change is
probably to allow physicians some leeway to practice
the art of medicine. However, this approach raises
many questions about the inclusion of these phrases
and the idea of shared decision making as a whole.
How was patient preference determined? Which pa-
tients were asked? What were the speciﬁc questions?
What tools were used to convey information? Is
this approach valid for minority ethnic groups that
have different cultural values when it comes to
seeking medical care? When all other recommenda-
tions in the guidelines come from rigorous analyses
of mounds of data, is there enough of an evidence
base to recommend shared decision making?
Although the idea to shift the spotlight away from
the physician and to each individual patient is very
noble, it is going to be difﬁcult to include this in a
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399structured guideline format. I need to be able to make
a sound decision about the clinical question. How I
apply it to the myriad of patients with the same dis-
ease is an art that I will master, 1 gray hair at a time.
Our performance standards are moving toward
the consumerism adage “the customer is always
right.” There is an increased pressure to achieve pa-
tient satisfaction. Various decision aids have been
designed to inform patients and increase participa-
tion in the decision-making process. A Cochrane
review of 115 studies concluded that decision aids
improve people’s knowledge regarding options and
reduce their decisional conﬂict related to feeling un-
informed and unclear about their personal values
(5). However, the same review also pointed out that
there is very little information about the degree of
detail that decision aids need in order to have a
positive effect on attributes of the choice made, or
the decision-making process (5). Section 3506 of the
Affordable Care Act (6) requires that the Secretary
of the Department of Health and Human Services
establish a program to develop tests and disseminate
certiﬁcated patient decision aids. The body of litera-
ture on shared decision making is relatively small.
The onus of decision making, which previously lay
solely with the physician, is now being transferred to
the patient. We are moving toward a system of
consultation that limits the responsibility of the
physician to that of effectively laying out the risks,
beneﬁts, and alternatives. It is especially difﬁcult
when it comes to 2 very distinct groups of patients
that we all deal with on a routine basis: the “non-
adherent” and the “well-informed.” These patients
make the same decision to not take the prescribed
medication, but for very different reasons. Do we
need tools for physicians to differentiate these 2
groups? Or do we no longer need to differentiatebetween them, because after giving them the in-
formation, we have to respect what they do with it.
What about the patient who does not want to partic-
ipate in this process? Is that a reasonable “patient
preference?” If given an option, some people might
choose not to take any medications. We do not yet
have enough evidence to say what the effect of
this approach would be on the population disease
burden. When there is so much uncertainty about
this approach, it is somewhat disconcerting that the
recent guidelines afﬁrm its routine application.
Although there is new recognition of patients being
at the center of their own care, the addition of phrases
like “patient preference” do not likely change the
basic principles of good medicine: communication
with patients, knowing them as people, understand-
ing their physiology and family history, and wanting
what is best for them. In fact, no decision should
be made without taking into account the personal
preferences of the patient. However, we should not
confuse this personalized care with patient prefer-
ence. There can never be a guideline that applies to
every patient that walks into my clinic. It will also
be challenging for patients to gain the same insights
that come from years of training by looking at 2-min
decision tools or scrolling through web pages. When
reading documents such as the clinical guidelines, the
question that I want answered by the experts is the
same question that patients often ask me in the clinic,
even after the most detailed, painstaking discussions
of risks and beneﬁts: “What should we do, doctor?”
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Priyanka Gosain, Division of Cardiovascular Dis-
eases, Mount Sinai Medical Center, 4300 Alton Road,
Miami Beach, Florida 33140. E-mail: priyanka.
gosain@msmc.com.RE F E RENCE S1. Stone N, Robinson J, Lichtenstein A, et al.
ACC/AHA guideline on the treatment of
blood cholesterol to reduce atherosclerotic
cardiovascular risk in adults: a report of the
American College of Cardiology/American
Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol 2014;63:
2889–934.
2. James P, Oparil S, Carter B, et al. Evidence-
based guideline for the management of high blood
pressure in adults: report from the panel membersappointed to the Eighth Joint National Committee
(JNC 8). JAMA 2014;311:507–20.
3. Chobanian A, Bakris G, Black H, et al. Seventh
report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of
High Blood Pressure. Hypertension 2003;42:
1206–52.
4. Nishimura R, Otto C, Bonow R, et al. AHA/ACC
guideline for the management of patients with
valvular heart disease: a report of the AmericanCollege of Cardiology/American Heart Association
Task Force on Practice Guidelines. J Am Coll Car-
diol 2014;63:e57–185.
5. Stacey D, Col N, Bennett C, et al. Decision aids
for people facing health treatment or screening
decisions. Cochrane Database Syst Rev 2014;1:
CD001431.
6. AffordableCareAct.Available at: http://www.hhs.
gov/healthcare/rights/law/patient-protection.pdf.
Accessed December 7, 2014.
Gosain J A C C V O L . 6 5 , N O . 4 , 2 0 1 5
Fellows-in-Training & Early Career Page F E B R U A R Y 3 , 2 0 1 5 : 3 9 8 – 4 0 0
400RESPONSE: “Actually, It’s More of a
Guideline Than a Rule”
Jonathan L. Halperin, MD
Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center,
New York, New York
E-mail: Jonathan.Halperin@mountsinai.orgThis quote is from Bill Murray in Ghostbusters, respond-
ing to Sigourney Weaver’s seductive advances, while
relaxing his rule to “never to get involved with possessed
people” (1).
Dr. Gosain has raised important issues pertinent to
applying clinical practice guideline recommendations in
patient care. Guidelines address diseases, tests, or treat-
ments; physicians must transform them into strategies for
patients. Shared decision making demands an awareness
of comorbidities and modiﬁers and a sensitivity to the
values and preferences that inﬂuence individual choices.
These preferences, founded upon beliefs, expectations,
and goals, help people balance the potential beneﬁts,
harms, costs, and utilities of clinical options in their own
perspective (2).
Few clinical practice guidelines provide adequate
guidance for patients with speciﬁc combinations of dis-
eases (3). And, as Dr. Gosain rightly points out, the evi-
dence supporting the selection of aids to communicate
particular recommendations is relatively weak and often
compromised by time constraints during patient-physician
encounters. More research is needed to enhance tools
that inform patients and optimize their ability to
share in treatment selections in the light of culture,economics, and the host of other factors that deﬁne the
context of care.
This is challenging for trainees and senior physicians
alike. Although a physician’s clinical experience can hone
an understanding of the implications of treatment de-
cisions, it can also introduce considerations that are not
contributory to the health of an individual patient (4).
Personalized and evidence-based medicine have in
common a need to distinguish patients based upon sus-
ceptibility to a disease or response to a speciﬁc treatment,
so that interventions can be directed selectively toward
those who will reap the most beneﬁt, and spare the ex-
pense and side effects for those who will not (5). This is
broadly applicable across the diagnostic and therapeutic
spectrum, but is particularly pertinent to choices involving
long-term strategies to reduce risk.
In describing this internal struggle, Dr. Gosain indicates
an important stage of professional development. The in-
terpersonal and communication skills that we draw upon
to inform and empower patients in shared decision
making are fundamental to the physician-patient rela-
tionship, as well as to building the trust and understand-
ing that are associated with treatment adherence and
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